Ampio Pharmaceuticals, Inc. AMPE

Full chart Compare
Set alert

Price alert · AMPE

All alert types
0.18 USD 0.00 (+0.00%)

At closeNov 3, 2026, 4:00 PM EST

0.0052 Day range 0.0052
0.0052 52-week range 0.6435
YTD
+3,421.15%
1 year
+3,421.15%
Market cap
207.88K
EPS (ttm)
-722.91
Shares out
1.14M
Forward P/E
-3.39
YTD return
+3421.15%
1-year return
+3421.15%
Volume
334
Open
0.0052
Previous close
0.1831
Day's range
0.0052 – 0.0052
52-week range
0.0052 – 0.6435
Beta
1.95
Analysts
Hold
Earnings date
Dec 24, 2024

2Y +0.1809 (+8222.73%)

0.00000.20000.40000.6000Jan 25Jun 25Nov 25Mar 26Aug 260.1831

Key statistics

Enterprise value
-2.97M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.08
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-5.37M
Total cash
4.12M
Total debt
451.00K
Return on equity
-113.96%
Short % of float
2.94%
50-day average
1.49
200-day average
2.82

Financials — quick view

All financials
AMPE Revenue — quarterly 0
2020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 2023
AMPE Net income — quarterly -2.05M
2020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 2023
AMPE EPS — quarterly -2.48
2020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 2023

Earnings

AMPE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 24, 2024Sep 1, 20240.00———
Oct 1, 2024Jun 1, 20240.00———
Jul 1, 2024Mar 1, 20240.00———
Mar 27, 2024Dec 1, 20230.00-2.48——
Nov 14, 2023Sep 1, 20230.00-1.53——
Aug 8, 2023Jun 1, 20230.00-1.80——

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on AMPE — it syncs with the Stock Master app.

Insider holders

AMPE insider holders
InsiderRelationLatest transactionDateShares held
BAR-OR DAVIDDirectorStock Award(Grant)Jan 3, 202192,800
BUCHI J KEVINDirectorPurchaseJun 8, 2023146,858
CHEREVKA HOLLIChief Operating OfficerStock Award(Grant)Oct 10, 2021500,000
COELHO PHILIP HDirectorSaleMay 20, 2021203,500
GILES RICHARD BDirectorStock Award(Grant)Jan 3, 2021367,121
MACALUSO MICHAELChief Executive OfficerStock Award(Grant)Oct 10, 20212,736,750

Institution ownership

AMPE institution ownership
Holder% heldSharesValueReported
HRT Financial LP0.69%5,20224.24KJun 29, 2023
Private Capital Management LLC0.32%2,39711.17KJun 29, 2023
Two Sigma Securities, LLC0.20%1,5077.02KJun 29, 2023
Renaissance Technologies, LLC0.19%1,4256.64KJun 29, 2023
Virtu Financial LLC0.17%1,2655.89KJun 29, 2023
Brighton Jones LLC0.16%1,2305.73KJun 29, 2023